Skip to main content
    P

    PAVmed Inc (PAVM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.63
    +0.29 (+21.73%)

    Market Cap: $13.03M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    PAVmed Inc (PAVM) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    PAVmed reported revenue of $71.00K for the fiscal year ended Dec 31, 2025, down 97.6% from the year before. That year, net income was -$2.47M with a net margin of -3477.5%, operating cash flow was -$5.21M and free cash flow was -$5.24M. The quarter ended Sep 30, 2026 had revenue of $41.00K and net income of -$13.04M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$71.00K-97.6%-207.0%-30712.7%-3477.5%
    Dec 2024$3.00M+22.1%-61.6%-1485.4%949.1%
    Dec 2023$2.45M+550.4%-161.8%-2805.7%-3232.6%
    Dec 2022$377.00K-24.6%-858.6%-24161.0%-27384.1%
    Dec 2021$500.00KN/A-17.0%-10878.6%-11225.2%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$71.00K$3.00M$2.45M$377.00K$500.00K$0$0$0$0$0
    Cost of revenue$218.00K$4.84M$6.42M$3.61M$585.00K$0$0$0$0$0
    Gross profit-$147.00K-$1.84M-$3.97M-$3.24M-$85.00K$0$0$0$0$0
    Research and development$4.49M$5.93M$14.28M$25.34M$19.85M$10.96M$6.63M$4.25M$2.62M$1.72M
    Operating income-$21.81M-$44.49M-$68.80M-$91.09M-$54.39M-$23.35M-$14.29M-$10.56M-$8.03M-$5.65M
    Net income-$2.47M$28.43M-$79.26M-$103.24M-$56.13M-$35.89M-$17.27M-$18.17M-$9.52M-$5.65M
    EBITDA-$2.31M-$38.34MN/AN/A-$52.48MN/AN/AN/AN/A-$5.65M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$41.00K$33.00K$22.00K$52.00K$5.00K$6.00K$8.00K$10.00K$996.00K$979.00K$1.01M$1.05M
    Gross profit-$117.00K-$89.00K-$75.00K-$34.00K-$50.00K-$35.00K-$28.00K-$39.00K-$385.00K-$687.00K-$734.00K-$561.00K
    Operating income-$6.73M-$7.02M-$8.04M-$6.80M-$4.84M-$4.71M-$5.45M-$5.19M-$11.58M-$13.68M-$14.04M-$16.38M
    Net income-$13.04M-$6.60M-$1.06M-$2.76M-$6.01M-$12.32M$18.62M$1.14M$60.71M-$14.91M-$18.51M-$17.41M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $11.10M exceeded cash and equivalents by $9.86M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$38.81M$30.66M$33.12M$53.98M$86.98M$19.78M$7.24M$8.50M$1.64M$870.42K
    Current assets$2.26M$2.16M$24.50M$43.93M$82.64M$18.94M$6.55M$8.46M$1.62M$741.17K
    Cash and equivalents$1.24M$1.19M$19.64M$39.74M$77.26M$17.26M$6.22M$8.22M$1.54M$585.68K
    Total liabilities$16.51M$37.69M$57.14M$43.05M$7.56M$20.25M$11.88M$10.97M$4.49M$1.19M
    Short-term debt$11.10M$29.10M$44.20M$33.65M$0$10.36M$8.14M$7.90M$0N/A
    Long-term debt$0N/AN/AN/AN/A$300.00KN/AN/A$1.94M$0
    Shareholder equity$33.97M-$2.50M-$53.83M-$9.68M$61.67M$1.90M-$3.82M-$2.31M-$2.85M-$319.07K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$35.21M$40.21M$45.42M$38.81M$38.07M$43.89M$52.82M$30.66M$30.55M$39.41M$37.25M$33.12M
    Total liabilities$25.08M$20.91M$20.43M$16.51M$12.28M$12.47M$11.89M$37.69M$39.94M$58.05M$57.83M$57.14M
    Cash and equivalents$3.63M$3.78M$6.46M$1.54M$3.10M$4.00M$2.70M$1.19M$765.00K$25.50M$25.54M$19.64M
    Shareholder equity$27.45M$35.05M$39.52M$33.97M$32.52M$37.53M$44.99M-$2.50M-$4.87M-$73.94M-$68.78M-$53.83M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$5.21M-$33.55M-$52.04M-$70.98M-$40.59M-$21.91M-$13.36M-$8.79M-$6.61M-$4.45M
    Capital expenditures$31.00K$55.00K$242.00K$1.54M$1.47M$55.00K$27.00K$26.61K$5.30K$21.79K
    Free cash flow-$5.24M-$33.61M-$52.28M-$72.53M-$42.06M-$21.97M-$13.38M-$8.81M-$6.61M-$4.48M
    Dividends paidN/AN/A$12.55B$35.23M$436.00M$357.00K$67.44B$7.10K$7.10K$7.10K
    Share repurchases$109.00K$0N/AN/A$1.31MN/AN/A$0$388.63K$0
    Investing cash flow-$31.00K-$16.18M$758.00K-$4.74M-$3.72M-$55.00K-$27.00K-$26.61K-$5.30K-$21.79K
    Financing cash flow$5.59M$31.28M$31.17M$38.21M$104.31M$33.01M$11.38M$15.50M$7.56M$4.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$2.42M-$2.66M-$2.62M-$1.55M-$896.00K-$1.18M-$1.58M$94.00K-$8.88M-$11.66M-$13.11M-$11.87M
    Capital expenditures$8.00K$13.00K$22.00K$14.00K$3.00K$8.00K$6.00K$4.00K$6.00K$3.00K$42.00K$183.00K
    Free cash flow$2.41M-$2.68M-$2.64M-$1.56M-$899.00K-$1.19M-$1.59M$90.00K-$8.89M-$11.66M-$13.15M-$12.06M
    Last 12 quarters

    Frequently Asked Questions About PAVM

    What is PAVmed's annual revenue?

    PAVmed reported revenue of $71.00K for the fiscal year ended Dec 31, 2025.

    How fast is PAVmed's revenue growing?

    Revenue was down 97.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -42.7%.

    Is PAVmed profitable?

    No. PAVmed reported net income of -$2.47M for the fiscal year ended Dec 31, 2025, with a net margin of -3477.5%.

    How much free cash flow does PAVM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.21M minus capital expenditures of $31.00K produced free cash flow of -$5.24M.

    How much debt does PAVmed have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $11.10M and cash and equivalents of $1.24M.